Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

AFLUNOV SUSPENSION FOR INJECTION 0.5ML IN PRE-FILLED SYRINGE [SIN14400P]

Active ingredients: INFLUENZA VIRUS SURFACE ANTIGENS (HAEMAGGLUTININ AND NEURAMINIDASE) A/TURKEY/TURKEY/1/05 (H5N1)-LIKE STRAIN USED (NIBRG-23)

View product's general information
Last updated on 9 October 2026

Product Info

AFLUNOV SUSPENSION FOR INJECTION 0.5ML IN PRE-FILLED SYRINGE

[SIN14400P]

Product information

Active Ingredient and Strength

INFLUENZA VIRUS SURFACE ANTIGENS (HAEMAGGLUTININ AND NEURAMINIDASE) A/TURKEY/TURKEY/1/05 (H5N1)-LIKE STRAIN USED (NIBRG-23) - 7.5 MCG HA/0.5 ML

Dosage Form

INJECTION, SUSPENSION

Manufacturer and Country

SEQIRUS VACCINES LIMITED (FORMULATION, FILL/FINISH, PRIMARY & SECONDARY PACKAGING) - UNITED KINGDOM
ROVI PHARMA INDUSTRIAL SERVICES, S.A. (FILLING/PRIMARY PACKAGING) - SPAIN

Registration Number

SIN14400P

Licence Holder

SEQIRUS PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

J07BB02

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 Therapeutic indications

Active immunisation against H5N1 subtype of Influenza A virus.
This indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing A/turkey/Turkey/1/2005 (H5N1)-like strain (see section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

AFLUNOV® should be used in accordance with official recommendations.

Dosing

4.2 Posology and method of administration

Posology:

Adults and elderly (18 years of age and above):
Individuals 18 years and older: Two 0.5 mL doses administered with an interval of at least 21 days between doses.

In the event of an officially declared influenza pandemic due to H5N1 virus, persons previously vaccinated with one or two doses of AFLUNOV® that contained HA antigen derived from a different clade of the same influenza subtype as the pandemic influenza strain may receive a single dose of adjuvanted H5N1 pandemic vaccine instead of two doses that are required in previously unvaccinated individuals (see section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Paediatric population:
There is limited experience in children between 6 months and 17 years of age (see section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Method of administration
Immunisation should be carried out by intramuscular injection into the deltoid muscle.

Contraindications

4.3 Contraindications

History of an anaphylactic (i.e. life-threatening) reaction to any of the constituents or trace residues (ovalbumin from eggs, kanamycin and neomycin sulphate, formaldehyde, cetyltrimethylammonium bromide (CTAB) and hydrocortisone) of this vaccine.
However, in a pandemic situation caused by the strain included in this vaccine, it may be appropriate to give this vaccine to individuals with a history of anaphylaxis as defined above, provided that facilities for resuscitation are immediately available in case of need.